Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
It is indicated for the treatment of pulmonary arterial hypertension (PAH) in adults and children aged 3 years and older, which can improve exercise tolerance and delay clinical de···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：5
It is indicated for the treatment of hyperprolactinemia in adults, including conditions caused by idiopathic factors or pituitary adenomas.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：6
This product is indicated for the treatment of adult patients with unresectable or metastatic melanoma harboring BRAF V600E or V600K mutations (in combination with vemurafenib), as···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：27
For the treatment of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia in adults and children 1 year of age and older.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：5
It is indicated for the treatment of adult patients with primary biliary cholangitis who have an inadequate response to or intolerance of ursodeoxycholic acid.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：19
It is indicated for the treatment of unresectable or metastatic melanoma, colorectal cancer, and non-small cell lung cancer with BRAF V600E or V600K mutations, and must be used in ···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：23
It is indicated for the treatment of adult and pediatric patients aged 3 years and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection. This includes ···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：5
It is mainly indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) harboring specific gene mutations (EGFR exon 19 deletion or exon 21 L858R substitution mut···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：5
Indicated for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer; neuroendocrine tumors of pancreatic, gastrointestinal, and pulmonary origin; advance···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：5
It is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have been confirmed to harbor EGFR exon 19 deletions or exon 21 (L8···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：4
A kinase inhibitor used in combination with rituximab for the treatment of relapsed chronic lymphocytic leukemia.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：27
It is indicated for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 gene abnormalities.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：32
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：1692025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4082024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：1632025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：1832025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：1632025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：1982025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：1762025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1712025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
